Drug Manufacturers - Specialty and Generic
Gland Pharma Limited (NSE: GLAND) breaks below support, falls 5%
Gland Pharma Limited (NSE: GLAND) stock price dropped 5% intraday to ₹2353.7, breaking below support in the Healthcare sector.
Gland Pharma Limited (GLAND) breaks below support, falling -5% today. This move comes as the stock has fallen below its 6M support trendline of ₹2649.02, signaling a breakdown. Gland Pharma, a large-cap specialty and generic drug manufacturer, has seen its stock decline despite positive sector momentum, indicating this may be a company-specific issue rather than a broader sector trend.
Technical setup — trendlines & DMA
Currently, Gland Pharma is trading well below its 6M support trendline, which ended at ₹2649.02, representing a 12.55% drop from this level. Resistance is noted at ₹2538.98, still above the current price by 7.87%. The 50-DMA stands at ₹2298.9, indicating the stock is trading 7.98% above this average, while the 200-DMA at ₹1905.3 shows a 30.29% increase from this longer-term average. Within its 52-week range of ₹1573.6 to ₹2573.5, the stock is in the upper third, suggesting that while there is room for further downside, a significant portion of potential gains has already been realized.
Snapshot: ₹2,353.70 on 2026-07-22 (chart frozen at publication)
Fundamentals & business context
With a PE ratio of 39.9 and profit margins at 16.0%, Gland Pharma’s valuation appears stretched relative to its current earnings, especially considering its revenue CAGR of 21.4%. The market seems to be pricing in future growth, but the current valuation may not fully reflect the company’s earnings power. Institutional ownership stands at 34.0%, indicating a moderate level of confidence from sophisticated investors. There was no specific NSE catalyst today that would explain the move, suggesting internal or market-driven factors may be at play.
Algorithmic scorecard
Gland Pharma’s overall score reflects a technically strong but fundamentally weaker profile. The strongest signals include excellent revenue growth with a CAGR of 21.4% and very low debt, indicating strong financial health and growth potential. However, the weakest signals are its overvalued status with a PEG of 4.16 and negligible dividend yield of 0.81%, suggesting limited income generation for investors and a valuation that may not align with its growth rate. These factors present a mixed picture for potential investors.
Company outlook
Management provided forward guidance of 12% to 13% consolidated top-line growth for FY ’27, driven by new product launches, GPO contracts, and the Cenexi business. They expect mid-teen EBITDA levels in the midterm for Cenexi and a CAGR of 15% over the next four years on a consolidated basis. Despite potential impacts from the Middle East conflict, costing 1% to 2% on revenue, ongoing cost optimization efforts aim to maintain profitability. Plans include investing INR2,000 crores over the next three years, with INR500 crores expected in FY ’27, to expand capacity and prepare for the full ramp-up of GLP-1 products by 2030.
Get all details on GLAND — P&L, peers, shareholding and more on TradeAlone.
Drug Manufacturers - Specialty and Generic
IPCA Laboratories Limited (NSE: IPCALAB) extends gains, moves up 10% intraday
IPCA Laboratories Limited (NSE: IPCALAB) stock price moves up 10% intraday to ₹1910.0, extending gains and nearing resistance at ₹1970.
IPCA Laboratories Limited (IPCALAB) extended gains by +10% to ₹1910.0 on the NSE on 17 Aug 2026, as the stock continues to consolidate upwards. This move is driven by the company’s robust financial performance and strategic initiatives, as reflected in its recent corporate announcements and management outlook. IPCALAB operates in the specialty and generic drug manufacturing sector, and today’s move aligns with its strong sector positioning and consistent growth trajectory.
Technical setup — trendlines & DMA
The current trendline structure for IPCALAB shows a 6M support floor at ₹1799.58, which is 5.78% below today’s price. Resistance is approaching at ₹1970, just 3.15% above the current price. The stock is trading at its 50-DMA of ₹1717.2, indicating a key momentum test. With the 50-DMA above the 200-DMA at ₹1542.5, the stock is in a bullish trend. IPCALAB is currently in the upper third of its 52W range, suggesting that a significant portion of its potential upside may already be priced in.
Snapshot: ₹1,910.00 on 2026-08-17 (chart frozen at publication)
Fundamentals & business context
With a PE of 37.9 and profit margins at 11.8%, IPCALAB’s valuation appears stretched relative to its current earnings, though its revenue CAGR of 15.5% and profit CAGR of 34.3% suggest strong growth potential. The 45.2% institutional ownership indicates that smart money has a positive view of the company’s prospects. There was no specific NSE catalyst today, but the stock’s move is consistent with its overall strong fundamental and technical picture.
Algorithmic scorecard
The overall algorithmic scorecard for IPCALAB reflects a balanced but slightly technically weak profile. The strongest signals are the revenue and profit CAGRs, which indicate robust growth, and the very low debt levels, showcasing excellent financial health. These factors suggest a company with solid growth prospects and minimal financial risk. However, the negligible dividend yield and weak momentum in the stock’s price growth over the past month are areas of concern. The low dividend yield may disappoint income-seeking investors, while the weak momentum could indicate a potential pullback or consolidation period ahead.
Company outlook
IPCA Laboratories Limited expects overall growth of around 12% to 13% on a consolidated basis for the current financial year, with an EBITDA margin of approximately 22% to 22.3%. The domestic branded business is guided for around 12% growth, with 1% to 2% coming from new product launches and the rest from price increases and volume. However, increased freight costs by around 25% in the fourth quarter are expected to impact profitability until the Iran-U.S. conflict issue is resolved. The company plans to launch around 18 to 20 products annually in the domestic market, 6 to 8 products in the U.S., and 3 to 4 products in each European and other markets. Ipca’s U.S. subsidiary, Pisgah Labs, is constructing a formulation facility expected to be commissioned in the fourth quarter of the current financial year.
Get all details on IPCALAB — P&L, peers, shareholding and more on TradeAlone.
Drug Manufacturers - Specialty and Generic
IPCA Laboratories Limited (IPCALAB) extends gains by 7% intraday
IPCA Laboratories Limited (IPCALAB) stock moves up 7% intraday to ₹1865.1, extending gains in the Healthcare sector.
IPCA Laboratories Limited (IPCALAB) extended gains by +7% to ₹1865.1 on the NSE today, pushing higher within its consolidating uptrend. The stock is near support at ₹1800, just 3.5% above it, and has not cleared resistance. This move comes after the company informed the Exchange about the Link of Recording for an analysts/institutional investor meet and the voting results from the Annual General Meeting held on August 13, 2026. IPCALAB operates in the specialty and generic drug manufacturing sector, and today’s move appears to be company-specific rather than a sector-wide momentum.
Technical setup — trendlines & DMA
The current trendline structure shows IPCALAB trading above its 6M support trendline at ₹1799.58, which is 3.51% below today’s price. Resistance is at ₹1970.17, with the stock currently 5.63% below this level. The 50-DMA at ₹1717.2 is above the 200-DMA at ₹1542.5, indicating a bullish trend. The stock is trading just above the 50-DMA, suggesting it is either extended or in a recovery phase. Within its 52-week range of ₹1251.6 to ₹1944.9, the stock is in the upper third, implying that a significant portion of the move is already priced in.
Snapshot: ₹1,865.10 on 2026-08-17 (chart frozen at publication)
Fundamentals & business context
With a PE of 37.9 and profit margins at 11.8%, IPCALAB’s valuation appears stretched relative to its current earnings. However, the revenue CAGR of 15.5% and profit CAGR of 34.3% suggest strong growth potential, which may justify the higher PE. The 45.2% institutional ownership indicates that smart money has a positive view of the company’s prospects. There was no specific NSE catalyst today, but the overall growth outlook and strategic plans outlined by management contribute to the stock’s performance.
Algorithmic scorecard
The overall algorithmic scorecard of 82 reflects a balanced view, with strong fundamental and technical signals. The two strongest signals are the revenue CAGR of 15.5% and profit CAGR of 34.3%, indicating robust growth. Additionally, the very low debt level with a D/E ratio of 0.16 points to excellent financial health. On the weaker side, the negligible dividend yield of 0.34% offers little income for investors, and the weak momentum with limited price growth over the past month suggests some caution. These factors collectively paint a picture of a company with strong growth potential but also some risks to consider.
Company outlook
IPCA Laboratories Limited expects overall growth of around 12% to 13% on a consolidated basis for the current financial year, with an EBITDA margin of approximately 22% to 22.3%. The domestic branded business is guided for around 12% growth, with 1% to 2% coming from new product launches and the rest from price increases and volume. However, freight costs have increased by around 25% in the fourth quarter, which is expected to impact profitability until the Iran-U.S. conflict issue is resolved. The company plans to launch around 18 to 20 products in the domestic market annually, with 6 to 8 products in the U.S. and 3 to 4 products in each European and other markets. Ipca’s U.S. subsidiary, Pisgah Labs, is constructing a formulation facility expected to be commissioned in the fourth quarter of the current financial year.
Get all details on IPCALAB — P&L, peers, shareholding and more on TradeAlone.
Drug Manufacturers - Specialty and Generic
Natco Pharma Limited (NATCOPHARM) moves down 6% intraday
Natco Pharma Limited (NATCOPHARM) experiences a 6% intraday decline to ₹892.6, signaling a breakdown in trendline status.
Natco Pharma Limited (NATCOPHARM) fell -6% to ₹892.6 on the NSE on 14 Aug 2026. The stock’s trendline status shifted from a breakdown to approaching resistance, which likely contributed to the decline. Natco Pharma is a specialty and generic drug manufacturer within the healthcare sector. Today’s move appears to be company-specific, as it does not align with broader sector momentum.
Technical setup — trendlines & DMA
The current 6M trendline structure shows a breakdown, with the stock now trading below the 6M support trendline of ₹914.01 by 2.40%. Resistance is at ₹839.43, which the stock has broken above by 5.96%. The 50-DMA at ₹917.5 is above the 200-DMA at ₹949.9, indicating a bearish trend. However, the stock is currently trading above both moving averages, suggesting some recovery. In the 52W range of ₹789.0–₹1226.8, the stock is in the lower third, implying that much of the downside is already priced in.
Snapshot: ₹892.60 on 2026-08-14 (chart frozen at publication)
Fundamentals & business context
With a PE of 12.0, Natco Pharma’s valuation appears reasonable given its strong profit margin of 34.8% and a robust revenue CAGR of 14.8%. The market seems to be pricing in the company’s solid growth trajectory rather than a turnaround. Institutional ownership stands at 12.6%, indicating a cautious but positive view from the smart money. There was no NSE catalyst today that directly influenced the stock’s movement.
Algorithmic scorecard
The overall algorithmic scorecard reflects a balanced view, with strong fundamental indicators offsetting weaker technical signals. Two of the strongest fundamental signals are the excellent profit margin of 34.8% and the undervalued PEG ratio of 0.47, suggesting the stock is cheap relative to its growth. Additionally, the very low debt level with a D/E ratio of 0.04 indicates excellent financial health. On the weaker side, the negligible dividend yield of 0.72% offers little income for investors, and the bearish trend signaled by the 50-DMA being below the 200-DMA suggests ongoing short-term pressure.
Company outlook
Natco Pharma’s management provided forward guidance expecting revenue of INR3,400-3,500 crores and PAT of INR700-750 crores for FY ’27. They anticipate growth in the Brazil subsidiary revenue to INR55-60 million and expect approvals for cancer pipelines in H2 of FY ’26-’27 with earnings impact in ’27-’28. The company aims to reduce earnings volatility by increasing base revenue contribution to 70% and special products to 25-30%. Additionally, Natco Pharma is exploring 1-2 large acquisitions to diversify its portfolio and build a global footprint. The company plans to invest in R&D with an expected expenditure of 7-9% next year and aims for 15-25% compounded growth in earnings from FY ’28 onwards.
Get all details on NATCOPHARM — P&L, peers, shareholding and more on TradeAlone.
-
Industrials3 days agoZen Technologies Limited to Acquire Majority Stake in Cogknit Semantics
-
BAJFINANCE2 days agoBajaj Finance Limited (bajfinance) Q2 FY27: AUM, PBT Surge, ROE Hits 20.6%
-
Energy3 days agoOil India Limited (OIL) Achieves Landmark Milestone with Special CBM Block Signing
-
AARTECH2 days agoAartech Solonics Limited’s Subsidiary Signs Mou for Energy Storage Cooperation
-
Consumer Defensive2 days agoKrishival Foods Limited (krishival) Appoints Vivek Kumar Jain as Chief Business Officer
-
Industrials2 days agoWaaree Renewable Technologies Limited (waareertl) Q2 FY27: 36.53% Yoy Revenue Growth
-
Basic Materials3 days agoVedanta Limited (vedl) Doubles Zinc Production Capacity in South Africa with $600 Mn Investment
-
Consumer Defensive2 days agoMangalam Global Enterprise Limited (mgel) Q2 FY27: PBT Rises 41.85% Yoy to ₹12.27 Crore; Strengthens NEAT Everyday Business Presence Across India